Clinical trials: Dementia Alzheimer Type
Alzheimer´s Disease
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to…
- Trial name
- NCT00818662
- Testing
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Where
- 41 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Baxalta now part of Shire
Prodromal Alzheimer's Disease
Combined tDCS and Cognitive Training in Alzheimer's
The General Objective of the study is to evaluate the short- and long-term efficacy of combining transcranial Direct Current Stimulation (tDCS) and cognitive training (CT) in patients with mild cognitive impairment due to…
- Trial name
- COMBINA-COG (NCT06861231)
- Testing
- Transcraneal Direct Current Stimulation (tDCS)- Active, Cognitive Training (CT)
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- University of Valencia
Alzheimer Disease
Comparison for the Patient With Alzheimer Disease the Impact of Three Different Groups of Patient Care
One of the interests of the Alzheimer Plan 2008-2010 is to provide increase support to helping families. It's also of major to involve the patient in the most active treatment possible, encouraging social inter relationship as…
- Trial name
- COMPARSE (NCT01639586)
- Testing
- respite platform, Day care, No access to a respite structure
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Department of Clinical Research and Innovation
Alzheimer Disease, Cognitive Impairment, Mild
Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease
Alzheimer's disease is a debilitating condition for patients and their caregivers marked by hallmark cognitive symptoms (e.g., memory loss) as well as an impact on quality of life.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild, Dementia, Mild
- Trial name
- NCT03384043
- Testing
- Smartphone Personal Assistant, Implementation Intention
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Baylor University
Dementia of Alzheimer Type
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).
- Trial name
- NCT04749563
- Testing
- IGC AD1
- Where
- Puerto Rico
- Volunteers
- 12 people
- Sponsor
- IGC Pharma, LLC
Alzheimer's Type Dementia
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.
- Trial name
- NCT01404169
- Testing
- E2020
- Where
- 32 sites in China
- Volunteers
- 260 people
- Sponsor
- Eisai Limited
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
Dementia, Alzheimer Type
Project COPE:Managing Dementia at Home
This study tests the effectiveness of an in-home intervention to reduce upset and burden among family caregivers, and decrease nursing home placement.
- Trial name
- NCT00259454
- Testing
- In-home intervention
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Dementia, Dementia Alzheimer Type
Plans4Care: Personalized Dementia Care on Demand
The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms…
- Conditions
- Dementia, Dementia Alzheimer Type, Alzheimer Dementia (AD), Memory Loss
- Trial name
- NCT07115251
- Testing
- Plans4Care
- Volunteers
- 160 people
- Sponsor
- Plans4Care Inc
Alzheimer Disease, Dementia
Development of NIC5-15 in the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.
- Trial name
- NCT00470418
- Testing
- NIC5-15
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
COVID-19
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China.
- Trial name
- CTCOVID-19 (NCT04313127)
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Alzheimer Disease, Dementia, Mild
Event-Related Potential (ERP) Components in Clinical Diagnosis
In this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether ERPs are now ready for validation as a tool…
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Trial name
- NCT05673759
- Testing
- Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Boston University
Genetic Predisposition, Paraganglioma
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic…
- Conditions
- Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS
- Trial name
- NCT06377033
- Testing
- Behavioral nudge
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease
Far Infrared Treatment for Alzheimer's Disease
Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.
- Trial name
- NCT00599469
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.
Alzheimer Disease, Dementia of Alzheimer Type
Assess Fibrin in Brains With AD/ADRD
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
- Trial name
- NCT05336695
- Testing
- PET/MR Imaging, 64Cu-FBP8
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
COVID-19
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
This phase III clinical trial is an endpoint-driven randomized, double-blind, parallel-controlled, multicenter clinical trial, and around 13,000 subjects aged 18 years and above who have previously received 1 dose of…
- Trial name
- NCT05124561
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT04623242)
- Testing
- Gantenerumab, Solanezumab
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles